News
Source: NASDAQ
- EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
- EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants
- EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
- EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors
- EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™
- EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information
- EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
- EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality
- EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- EyePoint Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
- EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officer
- EyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
- EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
- EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors
- EyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financing